Dr. Lanocha has disclosed that he received a $6,000 payment in the last year from the speakers’ bureau of Neuronetics, the makers of the NeuroStar TMS system. Dr. Carlat has reviewed this interview to ensure the absence of commercial bias, either in favor of any particular TMS product, or in favor of TMS over other treatment options. In a future issue of TCPR, we will review the most recent efficacy literature and will compare the pros and cons of specific TMS devices.